Evidence map›Paper›PMID 33857556›Full record

ReviewAdvanced drug delivery reviews2021

Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects.

M Brittany Johnson, Morgan Chandler, Kirill A Afonin

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Isothermal assembly of DNA nanostructures.Chemical communications (Cambridge, England) · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

M Brittany JohnsonDepartment of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Morgan ChandlerNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Kirill A AfoninNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. Electronic address: kafonin@uncc.edu.

Funding

SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responsesR35GM139587 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2021 to 2025
$1.8M
Characterization of various multifunctional nucleic acid nanoparticles and understanding their immunotoxicityR01GM120487 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2017 to 2020
$1.5M
NIGMS NIH HHS R01 GM120487NIGMS NIH HHS R35 GM139587
6 · The paper itself

Abstract

Nucleic acid nanoparticles (NANPs) represent a highly versatile molecular platform for the targeted delivery of various therapeutics. However, despite their promise, further clinical translation of this innovative technology can be hindered by immunological off-target effects. All human cells are equipped with an arsenal of receptors that recognize molecular patterns specific to foreign nucleic acids and understanding the rules that guide this recognition offer the key rationale for the development of therapeutic NANPs with tunable immune stimulation. Numerous recent studies have provided increasing evidence that in addition to NANPs' physicochemical properties and therapeutic effects, their interactions with cells of the immune system can be regulated through multiple independently programmable architectural parameters. The results further suggest that defined immunomodulation by NANPs can either support their immunoquiescent delivery or be used for conditional stimulation of beneficial immunological responses.

Indexed as

AnimalsDrug Delivery SystemsHumansNanoparticlesNucleic AcidsNucleic AcidsDrug deliveryImmune responsesImmunostimulationImmunotherapyNANPsPRRRNA nanotechnology

Identifiers

PMID33857556
PMCPMC8178219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.